
mPath
Therapeutics
TRAUMA • RELIEF

Re-Defining Recovery from Trauma and Addiction with Historical Natural Medicine & Empathetic Aftercare

WHY WE ARE HERE
TACKLING UNNECESSARY SUFFERING, NATURALLY
50 Million Americans Battle Trauma and Addiction Disorders with Little Hope of Permanent ReliefConventional Pharmaceuticals Treat Only Symptoms—Temporarily—Resulting in Unnecessary Relapse Rates, Continued Dependencies, and SufferingWellness Centers Abroad Offer Alternative Therapies with inconsistent dosage, poor quality and supply, often from illicit sourcesForeign Providers Operate Primarily from non-medical facilities and unregulated clinicsClinics Abroad Offering Alternative Therapies are Capturing Mainstream Appeal Due to Highly Promising Studies at Leading American Institutions
mPath Therapeutics Corporation Enjoys Unique Capability to Safely Produce Novel All-Natural Drug Shown Highly Effective in Long Term Recovery from PTSD, Traumatic Brain Injury and Addiction DisordersmPath Therapeutics Will Produce Government Approved, GMP-Certified Pharma-Grade Medicine, Shipping from Free Trade Zone to Clinics WorldwidemPath Treatments Take Place in Hospital-Administered Clinics in Jamaica, Known for its Regulatory Support for Alternative TherapiesClick this link for a graphic illustrating the scale of disorders that Ibogaine addressesClick this link for a comprehensive list of citations, research, references, and reporting

2-FRONT SOLUTION
PIONEERING TREATMENT
+ FIRST-CLASS CARE
mPath Therapeutics purpose is to standardize and manufacture the world’s first certified all-natural medicine shown to help patients accelerate and stabilize recovery from the crippling effects of PTSD, Traumatic Brain Injury, Opioid Addiction, and related disorders including chronic pain, depression, and anxiety.Our mission is to be the leading developer of all-natural, life-affirming therapies driven by rigorous hospital-administered treatment, and compassionate, evidence-based therapeutic rehabilitation and aftercare.mPath Therapeutics is led by a group of distinguished experts and business builders. Team profiles can be viewed here.




SAFETY FIRST
HOSPITAL ADMINISTERED
While Ibogaine has shown great promise in treating addiction, it is not without risks and may not be appropriate for individuals with certain medical conditions such as heart problems or psychiatric disorders. mPath’s intake process involves thorough medical evaluation, full blood analysis, pre-screening for cardiac issues, as well as interactions with certain medications or drugs.Ibogaine treatment should only be administered under medical supervision in a controlled environment—mPath Ibogaine treatment is administered in a hospital under physician supervision.Here is a list of Frequently Asked Questions

LASTING RECOVERY
SALES • REHABILITATION • AFTERCARE
mPath fills a critical gap by providing legal, ethically sourced, pharmaceutical-grade Ibogaine, standardizing drug consistency, facilitating safer treatment at the countless centers currently performing Ibogaine therapy worldwide.mPath will standardized protocols for Ibogaine treatment and rehab at partner hospitals and clinics in Jamaica, opening new clinics worldwide as demand grows and regulations permit.mPath aftercare & co-therapy retreats personalize decompression and nurture empowerment for patients, families, and caregivers, providing tools for the journey to full recovery, together—anchored in a supportive community for lasting results.
Pioneering
natural
relief

ESTABLISHED • GROWING
GMP-CERTIFIED PRODUCTION
mPath Therapeutics was launched by legacy executives steeped in holistic medicines with established pharmaceutical operations on-island. Over $5M USD was invested in state of the art manufacturing facilities, modern offices and key licenses. mPath access to these lucrative assets will accelerate drug development, production and distribution to a growing international customer base.

RE-DEFINING RECOVERY
57 MILLION SUFFERING TRAUMATIC DISORDERS ANNUALLY
Ineffective treatments lead to continued abuse and prolonged suffering. Conventional pharmaceutical Medication-Assisted-Treatments don’t consider causation and brain chemistry, often leading patients to self-medicate with illicit drugs or seek treatment at foreign clinics able to offer promising alternative therapies unavailable in the U.S. under current FDA regulations, yet still sourcing risky black/gray market iboga powder.mPath will commence operations by administering clinical trials at our facilities in Jamaica with up to 20 veterans, at no cost.And while veterans are more commonly associated with traumatic disorders, 80% of Americans suffering from PTSD are not veterans.We have much work to do.


NEXT PHASE
GROWTH STAGE
mPath Therapeutics Corporation is currently raising $1M to fund Stage 1 & 2 developments:1) Supply existing clinics worldwide with first government-approved, pharma-grade, dosage precise Ibogaine produced in-house at existing GMP-certified facility.2) Develop Treatment and Aftercare Protocols and intellectual property from our headquarters in Jamaica, triggering a license to begin on-island patient treatment.If you have been personally affected by trauma or addiction--that's why we're here and we want to hear from you. If you would like to discuss joining us in this seed round, please contact us using the form below and we will reply directly. If you're seeking safe relief from trauma and related disorders, we want to hear from you, too.
CONTACT US
We look forward to any comments or questions.
Thank you for your interest in mPath Therapeutics
Click here to review STATS, TEAM, FAQs & FACTS
mPath Therapeutics™ and all content copyright mPath Therapeutics, Inc © 2025